Product Specific Agreement – Clinical Product Drug Substance Sample Contracts

SAMSUNG BIOLOGICS CO., LTD. AMENDMENT NO 1 TO PRODUCT SPECIFIC AGREEMENT – CLINICAL PRODUCT DRUG SUBSTANCE

Product Specific Agreement – Clinical Product Drug Substance • February 27th, 2023 • Fibrogen Inc • Pharmaceutical preparations

• Contract Type
  Product Specific Agreement – Clinical Product Drug Substance
• Filed
  February 27th, 2023
• Company
  Fibrogen Inc
• Industry
  Pharmaceutical preparations

This Amendment No. 1 to the Product Specific Agreement – Clinical Product Drug Substance (this “Amendment No. 1”) is made effective as of the date of last signature below (the “Amendment No. 1 Effective Date”) by and between FibroGen, Inc., a Delaware corporation having its principal place of business at 409 Illinois Street, San Francisco, California, USA 94158 (“Client”) and Samsung Biologics Co., Ltd., a Korean corporation having its principal place of business at [*] (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.